In conclusion we have shown that ACE-I treatment is able to modulate mesangial cell surface expression of LRP providing an additional mechanism whereby ACE-Is can mediate anti-fibrotic actions independent of their haemodynamic actions Low density lipoprotein receptor related protein (LPR) is a widely expressed, multifunctional endocytic and signalling receptor implicated in the modulation of a number of cellular processes including lipoprotein catabolism, blood coagulation, cell adhesion and migration [1] . Among its many functions, LRP modulates the turnover of proteases and protease inhibitor complexes and is known to be a clearing receptor for tissue plasminogen activator (tPA) [1, 2] . LRP expression is also associated with regulating extra cellular matrix deposition since it mediates fibronectin catabolism and inhibits fibronectin accumulation on cell surfaces [3] . More recently, however, it has been found that these receptors may play an important role in cell signalling [1] .
We have previously shown that the angiotensin converting enzyme inhibitor (ACE-I) perindoprilat exerts anti-fibrotic effects in human mesangial cells via the bradykinin/tPA axis [4] . In these experiments perindoprilat was able to reduce macrophage conditioned medium (MPCM)-induced fibronectin levels while concomitantly upregulating tPA mRNA levels. Paradoxically, however, supernatant tPA protein levels were reduced. Tissue plasminogen activator is generally thought to be beneficial in the pathogenesis of fibrosis because of its ability to increase matrix degradation and decrease matrix accumulation [5] . These observations led us to speculate that reduced supernatant tPA protein levels following treatment with an ACE -I could occur as a result of a faster turnover/clearance rate of the protease mediated by a receptor such as LRP. We would therefore hypothesise that ACE-I treatment leads to increased binding/endocytosis of tPA which initiates the down stream events that lead to the reduction of MPCM-induced fibronectin in human mesangial cells.
The aim of the present study therefore was to test the hypothesis by investigating the possible relationship between ACE-I treatment and LRP expression, and the subsequent events, which lead to observed reduction in fibronectin levels in human mesangial cells.
Experimental procedures
Cell culture-Human mesangial cells were cultured from the glomerular explants processed from the normal poles of nephrectomised human kidneys with renal carcinoma using standard serial sieving techniques [4] . All donors had given consent for post-surgical use of their kidneys and procedures on donated kidneys had been approved by ethical committee. The cells were cultured in RPMI 1640 (Invitrogen, Paisley, UK) supplemented with 20% heat inactivated fetal calf serum (FCS) (Sigma, Dorset, UK), 5μg/ml bovine insulin (Sigma), 100U/ml penicillin (Invitrogen), 100μg/ml streptomycin (Invitrogen), and 2mM glutamine (Invitrogen). Mesangial cells of passage 2 through 10 were cultured in 75cm 2 flasks (Costar-Corning, Buckinghamshire, UK). For experiments mesangial cells were grown to confluence in 24-well plates (Costar Corning) or 25cm 2 flasks (Costar-Corning) and then rendered quiescent in RPMI medium containing 0.5% FCS for 48 h prior to use. All experiments were carried out in RPMI +0.5% FCS. Cells of the human monocyte/macrophage cell line U937 (ECCAC no. 85011440) were grown in RPMI 1640 supplemented with 10% FCS, 100U/ml penicillin, 100μg/ml streptomycin and 2mM glutamine. Preparation of U937 cell conditioned medium-U937 cell conditioned medium was prepared as previously described [4] . Preparation of cell lysates -After removal of tissue culture supernatants, cell monolayers were washed with PBS, scraped into 250μl 1% IGEPAL CA-630 (Sigma) in wash buffer (PBS containing 0.3M NaCl and 1% Tween 20), and then incubated at room temperature for approximately 30 min. The cell scrapings were transferred to 2ml tubes, sonicated with a 5s burst and centrifuged for 1min at 11 600 x g. Sonication and centrifugation were repeated, and the lysate supernatants were assayed for total cell protein.
Culture of mesangial cells in the presence of macrophage conditioned medium (MPCM)-Confluent, quiescent mesangial cells were exposed to a 50% solution of MPCM in the presence or absence 40μM of the ACE-I perindoprilat (gift from Servier, France) or in the presence or absence of 500nM receptor associated protein (RAP)(Calbiochem, Nottinham, UK). The cultures were maintained in the various conditions for 1 or 3 days. The tissue culture supernatants were harvested and stored at -20ºC for subsequent analysis. For Northern analysis mesangial cells were exposed to 50% MPCM ± additions for approximately 18 h prior to RNA processing. Fibronectin ELISA -Culture supernatants were assayed for fibronectin as previously described [4] . LRP Binding assay-Assay was adapted from the protocol described by Salicioni et al [3] . 100μl of 10μg/ml human plasma fibronectin (Calbiochem) was immobilised onto 96 well microtitre plates (Costar-Corning) overnight at 4ºC. 10μg/ml BSA (Sigma) was coated onto parallel plates to serve as a negative control. Non-specific binding sites blocked with 2% (w/v) BSA for 1 h. Cell lysates from mesangial cells exposed to MPCM± ACE-I or medium alone were added to the wells at dilutions of 1:10, 1:50 and 1:100 and incubated for 2 h. In parallel cell lysates were also incubated in the presence or absence of purified 4nM alpha-2 macroglobulin (α2mac)(Serotec, Oxford, UK). After washing the plates any LRP in the lysates that bound to immobilised fibronectin was detected using an anti-CD91 mouse monoclonal antibody (Serotec) at a 1:100 and incubated for 2 h. Bound primary antibody was detected with horseradish peroxidase labelled anti-mouse IgG antibody (DakoCytomation, Ely, UK) at a dilution of 1:1000 and incubated for 1h. OPD (DakoCytomation) was used as the chromogenic substrate as described for the fibronectin ELISA [4] . Flow cytometry -Confluent, quiescent mesangial cells were stimulated with MPCM ± ACE-I for 18 h. Cell monolayers were washed in PBS containing 0.1% BSA and 0.05% sodium azide (PBA) after which the cells were detached from the flask surface using trypsin-EDTA (Invitrogen). The cells were then washed in 5ml PBA before being resuspended in 50μl of either anti-CD91 at 1:10 dilution or in PBS only. After 40 min incubation on ice the cells were washed twice in PBA and then resuspended in 50μl goat F(ab') 2 anti-mouse Ig-FITC labelled antibody (DakoCytomation) at 1:50 dilution. FITClabelled secondary antibody alone was used as a negative control. After 30min incubation on ice the cells were washed twice in PBA and resuspended in 500μl PBA for analysis of median fluorescence on a flow cytometer (FACScan, Becton Dickinson). Western Blotting-Cell monolayers from each well were scraped into 150μl non-reducing sample buffer. The samples were boiled for 5min and resolved on 7% SDS-polyacrylamide gels. The gels were blotted onto nitrocellulose membranes and immunostained. Briefly, the membranes were blocked with a 2% solution of BSA in TTBS (TBS containing 0.5% Tween 20) for 1hr. The membranes were then washed once in TTBS prior to incubation with anti-LRP antibody (1:100), for at least 2hr at room temperature. After 3 more washes the membranes were incubated with alkaline phosphatase-labelled rabbit anti mouse immunoglobulins for at least 2hr at room temperature. The membranes were washed a further 3 times before addition of chromogenic substrate (SigmaFast™ BCIP/NBT tablets). Protein Determination -The protein content of cell lysates dissolved in 1% IGEPAL was determined using a commercial BioRad DC protein assay (BioRad, UK) using BSA standards according to the manufacturer's instructions.
Gelatin Zymography -Culture supernatants were mixed 1:1 with non-denaturing sample buffer and resolved at 4°C on 8% SDSpolyacrylamide gels containing 2.5mg/ml gelatin (electrophoresis grade, 300 bloom) (Sigma). The gels were washed in 2.5% Triton X 100 (Sigma) for approximately 1h after which they were incubated overnight at 37ºC in pH7.6 developer buffer (50mM Tris-HCl, 100mM NaCl, 10mM CaCl 2, 0.05% (w/v) Brij) The gels were then stained with Brilliant Blue R® (Sigma) and destained with a solution of 40% methanol 10% acetic acid. Destained gels were dried and bands of lysis scanned using a BioRad imaging densitometer (model GS-700). Fibrinogen zymography -Culture supernatants were mixed 1:1 with non-denaturing sample buffer and resolved at 4°C on 11% SDSpolyacrylamide gels containing 12mg fibrinogen (Calbiochem), 10U plasminogen (Calbiochem), 10U thrombin (Calbiochem) per 10ml gel. Following electrophoresis the gels were washed, incubated in developer and stained as described for gelatin zymography. Northern blotting-Northern analysis was carried out using a method previously described [4] . RT-PCR -0.5μg aliquots of total RNA were reverse transcribed using AMV reverse transcription system (Promega, Southampton, UK) according to the manufacturer's instructions. The resulting cDNA was amplified using ReddyMix™ PCR Mastermix (ABgene, Surrey, UK) and 50pmol of specific sense and anti-sense primers. Thermocycling conditions were optimised for each primer pair. Amplicons were resolved by electrophoresis on 1% Trisacetate EDTA (TAE)-agarose gels. Oligonucleotide primers-Reverse transcriptionpolymerase chain reaction (RT-PCR) of RNA extracted from mesangial cells stimulated with MPCM was carried out using the following primers (custom made by Invitrogen): LRP sense 5'-CCT ACT GGA CGC TGA CTT TGC-3', antisense 5'-GGC CCC CCA TGT AGA GTG T-3' [6] , MMP9 sense 5'-AAG TAC TGG CGA TTC TCT GAG GG-3', antisense 5'-GGC TTT CTC TCG GTA CTG GAA GAC-3' [7] , MMP2 sense 5'TTT TCT CGA ATC CAT GAT GG-3', antisense 5'-CTG TG CAG CTC TCA TAT TT-3' [8] . 
RESULTS
Receptor associated protein (RAP) is the most avid ligand of LRP [9] and as such binds to LRP at the expense of other ligands. In order to examine whether ACE-Is play a role in LRPmediated binding or endocytosis of tPA, RAP (500nM) was added to MPCM-injured cells in the presence or absence of the ACE-I perindoprilat. As previously observed [4] the culture supernatants of MPCM-injured cells treated with ACE-I contained lower tPA levels than those from non-treated cells. Addition of RAP resulted in the accumulation of tPA in mesangial cell supernatants approximately doubling levels compared to non RAP treated cells. (Fig 1a) Supernatant tPA levels were typically 8.37±0.82 ng/ml (0.1ng/μg cell protein) in MPCM injured cells and 1.63±0.17 ng/ml (0.012ng/μg cell protein) in control cells while cell lysate tPA levels were typically 27.1±4.4ng/ml (0.32ng/μg cell protein) in injured cells and 6.39±1.1ng/ml (0.07ng/μg cell protein) in control cells. RAP did not have the same cumulative effects on PAI-1 levels. However, RAP did reverse the perindoprilat-induced PAI-1 lowering effects which we have previously reported [4] The tPA assay data were supported by fibrinogen gel zymography on culture supernatants, which showed an accumulation of tPA activity in the presence of RAP (Fig 2) . Mesangial cell lysates were analysed for the presence of immunoreactive tPA to assess whether the apparent ACE-I-induced reduction in tPA levels from culture supernatants could be accounted for by binding to, or uptake by, mesangial cells. The results demonstrated that tPA levels in the lysates from cells treated with ACE-I were higher than those in non-treated cells (Fig 1b) indicating that uptake of tPA by mesangial cells was enhanced in the presence of ACE-I. As observed in the supernatants, lysate tPA levels were also higher in RAP treated cells than cells treated with MPCM alone. However, there was no significant difference in lysate tPA levels between ACE-I treated cells regardless of whether they had been treated with RAP or not.
The ability of perindoprilat to decrease MPCM-injured mesangial cell fibronectin levels was diminished in the presence of RAP, although RAP itself appeared to have no effect on the fibronectin levels in non ACE-I treated cells (Fig  3) . The fact that fibronectin levels were not further reduced in the presence of accumulated tPA would suggest that tPA itself was not directly responsible for the observed fibronectin degradation as a result of its own protease activity or indirectly via plasmin and the subsequent activation of zymogens such as MMP2. Rather, it suggests that uptake of tPA results in the degradation of fibronectin perhaps via a mechanism down stream of tPA binding. It is possible that RAP-mediated inhibition of tPA binding results in reduced receptor signalling and diminution of the consequent down stream events which ultimately result in fibronectin degradation. We have previously observed (unpublished data) that addition of exogenous tPA (100ng/ml = 40u/ml = 1.5nM) to MPCMstimulated mesangial cells resulted in a 15.34±2.1% reduction in MPCM-induced fibronectin levels. In the current study the levels of accumulated tPA were of the order of 20ng/ml and therefore probably insufficient to induce observable fibronectin degradation.
Tissue plasminogen activator is known to signal, as a cytokine via LRP causing increased transcription of MMP9 [10, 11] . RT-PCR was carried out to assess mesangial cell expression of MMP9 and MMP2 mRNA in response to ACE-I treatment. RT-PCR demonstrated that MMP9 mRNA levels were upregulated in response to ACE-I (MPCM 0.662±0.105, MPCM+ACE-I *1.35±0.27, med 0.61±0.2 arbitary densitometric units, *p<0.03 vs MPCM, n=4) while MMP2 mRNA levels appeared unaffected (Fig 4a) . However, gelatin zymography on culture supernatants from MPCM-injured, ACE-I treated mesangial cells unexpectedly showed lower MMP9 activity than supernatants from non-ACE inhibitor treated cells (reduction in the active form of MMP9 was particularly pronounced) (Fig 4b) . Co-incubation of MPCM-injured mesangial cells ± ACE-I in the presence of RAP was able to at least restore ACE-I-reduced MMP9 activity (Fig 4b) . Since LRP can also function as a scavenger for MMP9 clearance [12] , this may explain the observed reduction in MMP9 activity in supernatants from cells grown in the presence of ACE-I. In the presence of ACE-I active MMP2 enzyme levels were slightly increased. Treatment with RAP appeared to have no effect on MMP2 activity.
In order to confirm the role played by LRP in the anti-fibrotic actions of ACE-I we wished to assess whether ACE-I treatment affected the surface expression of LRP.LRP is known to have a fibronectin-binding domain within its structure [3] . This property of LRP was exploited to see whether increased levels of LRP could be detected in mesangial cell lysates following ACE-I treatment. Our data demonstrated that lysates from ACE-I treated cells were able to bind to immobilised fibronectin at higher dilutions than lysates from non-ACE-I treated cells (at the 1/50 dilution lysates from ACE-I treated cells bound significantly more fibronectin (p<0.03) than the same dilution in non-ACE-I treated cells. However, at the 1/100 dilution there was no significant difference in the binding between treatments) (Fig 5a) . In the presence of α-2-macroglobulin, which competes for binding to LRP, this dilution effect was attenuated (Fig 5b) .
Flow cytometry using antibodies to LRP demonstrated that MPCM-injured cells bound 37% more LRP antibody than control cells but cells treated with ACE-I bound 50% more than control cells (Fig 6a) . Western blotting also reflected this small increase in LRP protein expression in response to ACE-I treatment (Fig  6b) .
Northern blotting carried out on RNA extracted from cells following 24hr exposure to MPCM in the presence or absence of ACE -I demonstrated that there was no change in LRP mRNA message expression at this time point, possibly suggesting that the ACE-I exerted its effect at the level of protein expression (Fig 7) . DISCUSSION Until very recently tPA had been regarded as an important component of the plasminogen activator system involved in the attenuation of extracellular matrix accumulation leading to the reduction of fibrosis after renal injury. Indeed it was in such a capacity that we tentatively ascribed the role of tPA when we demonstrated that the anti-fibrotic effects of ACE-I in mesangial cells were modulated via the bradykinin / plasminogen activator system axis [4] . A number of studies have shown that the role of tPA is far more complex and as a result, the functional role of tPA has been dramatically revised. It is now believed that tPA also plays an important, plasmin-independent, stimulatory, cytokine-like role responsible for a diverse number of physiological functions including the regulation of endothelial cell proliferation [14] , modulation of neuron apoptosis [15] and transcriptional up regulation of MMP9 [10, 11] . It must be said, however, that tPA's multifarious plasmin dependent and independent functions are not mutually exclusive.
LRP, amongst its many functions, is able to control the 'fibrotic status' of its immediate environment. It is involved in the catabolism of extracellular matrix protein like fibronectin [3] as well as the homeostasis of proteinases like tPA and MMP9 [1] . LRP deficient murine embryonic fibroblasts have been shown to exhibit increased levels of cell surface fibronectin without the biosynthesis of the matrix protein having been altered [3] . Similarly antagonism of LRP with RAP has been shown to increase fibronectin accumulation in wild type fibroblasts. Transfection of full length LRP into deficient cells has also been shown to decrease fibronectin levels [3] . The current study has demonstrated that treatment with ACE-I results in altered LRP expression, which may have occurred posttranscriptionally since no changes in LRP mRNA levels were observed 24hr post treatment. The apparent increase in surface expression of LRP as seen in the presence of MPCM compared to control (medium alone) may be attributed to a decreased rate of receptor cycling that can occur in the presence of an injurious agent [16] , in this case MPCM. This phenomenon may also contribute to the observed accumulation of fibronectin in the presence of MPCM, as reduced cycling would ultimately delay fibronectin degradation. ACE-I treatment may therefore facilitate an increase in LRP cycling rates or alter the subcellular distribution such that receptors are more rapidly translocated from the endoplasmic reticulum to the surface of the cell such as has been found previously in vascular smooth muscle cells following treatment with epidermal growth factor and platelet derived growth factor [16] .
Studies have shown that treatment of murine fibroblasts with RAP causes an accumulation of MMP9 due to inhibition of LRP's ability to scavenge MMP9 [11] . In the current study we did not observe an accumulation of MMP9 in the presence of RAP but rather an accumulation of tPA, suggesting that in our system RAP was blocking the binding and endocytosis of tPA and thereby the subsequent signalling required to up regulate the expression of MMP9. We could speculate that these increased levels of intracellular tPA could be the consequence of a RAP-induced deceleration of the receptor cycling process resulting not only in an accumulation of extracellular tPA but also increased intracellular tPA as a result of a reduced rate of tPA degradation.
We observed a paradoxical decrease in MMP9 activity in ACE-I treated, MPCM-injured mesangial cells, which was at least restored on treatment with RAP. This suggests that increased LRP surface expression as well as resulting in increased MMP9 mRNA expression may also be responsible for an increased rate of MMP9 protein being scavenged from the culture supernatants. This observation suggests that a dynamic balance exists between tPA binding and signalling leading to the up regulation of MMP9 expression, and tPA and MMP9 endocytosis leading to clearance of the proteases via the same receptor. MMP2 mRNA levels did not appear to be affected by ACE-I treatment. The change in enzyme activity therefore probably represents a post-translational change in preformed zymogen levels.
Whether the ACE-I-mediated effects on LRP expression are the result of a direct action of ACE-I molecules on LRP or are the consequent down stream effects of ACE-Iinduced tPA acting as a cytokine via LRP remains to be determined.
The dose of 40μM perindprilat used in the current study was based upon a dose response curve carried out for a previous study [4] . This equates to a concentration of 14.7μg/ml which is higher than the peak plasma concentration (Cmax) of either perindopril (prodrug) or perindoprilat typically observed following a single 4mg dose, in a human subject (64ng/ml and 4.7mg/ml respectively) [18] , (although patients can receive up to 8mg/day). However, direct comparisons between in vivo and in vitro are problematic since the pharmacokinetics of a drug in cell culture will be different to those of the same drug in a human subject. Moreover, patients are dosed daily over long periods of time while cells in the current study were exposed to a single dose for 1 or 3 days. Whether the observed in vitro effects also occur in human patients receiving perindopril is still to be fully determined. However, the study has identified LRP as a possible target of ACE-I action and provides a platform for future research.
In conclusion, we have demonstrated for the first time that ACE-I treatment results in the modulation of mesangial cell surface expression of LRP, potentially allowing for increased fibronectin catabolism, and tPA binding and signalling -beneficial anti-fibrotic effects that are independent of ACE-I haemodynamic actions.
The abbreviations used are: LRP, Low density lipoprotein receptor related protein; RAP, receptor associated protein; macrophage conditioned medium, MPCM; ACE-I, angiotensin converting enzyme inhibitor; α2mac, alpha-2 macroglobulin. 
